SFO
ABBV icon

Stokes Family Office’s AbbVie ABBV Stock Holding History

Stokes Family Office’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.6M Sell
18,285
-7,491
-29% -$1.61M 0.54% 57
2026
Q1 		$5.61M Sell
25,776
-1,919
-7% -$426K 0.58% 45
2025
Q4 		$6.33M Buy
27,695
+2,470
+10% +$563K 0.58% 43
2025
Q3 		$5.84M Buy
25,225
+115
+0.5% +$23.4K 0.55% 48
2025
Q2 		$4.66M Buy
25,110
+1,009
+4% +$188K 0.49% 52
2025
Q1 		$5.05M Sell
24,101
-2,991
-11% -$581K 0.57% 42
2024
Q4 		$4.81M Buy
27,092
+3,057
+13% +$562K 0.51% 47
2024
Q3 		$4.75M Buy
24,035
+209
+0.9% +$39K 0.52% 45
2024
Q2 		$4.09M Buy
23,826
+504
+2% +$83.5K 0.48% 51
2024
Q1 		$4.25M Sell
23,322
-490
-2% -$84.4K 0.53% 49
2023
Q4 		$3.69M Sell
23,812
-3,657
-13% -$533K 0.5% 50
2023
Q3 		$4.09M Buy
27,469
+116
+0.4% +$17K 0.48% 51
2023
Q2 		$3.69M Buy
27,353
+51
+0.2% +$7.48K 0.43% 53
2023
Q1 		$4.35M Sell
27,302
-689
-2% -$105K 0.54% 37
2022
Q4 		$4.52M Buy
27,991
+603
+2% +$92.5K 0.58% 42
2022
Q3 		$3.68M Buy
27,388
+381
+1% +$54.7K 0.52% 45
2022
Q2 		$4.14M Sell
27,007
-83
-0.3% -$12.7K 0.56% 42
2022
Q1 		$4.39M Buy
27,090
+531
+2% +$77.1K 0.58% 43
2021
Q4 		$3.6M Buy
26,559
+490
+2% +$57.9K 0.45% 53
2021
Q3 		$2.81M Sell
26,069
-128
-0.5% -$14.6K 0.39% 55
2021
Q2 		$2.95M Buy
26,197
+295
+1% +$33.2K 0.42% 52
2021
Q1 		$2.8M Buy
25,902
+915
+4% +$97.9K 0.44% 53
2020
Q4 		$2.68M Buy
24,987
+509
+2% +$48.9K 0.53% 47
2020
Q3 		$2.14M Buy
24,478
+932
+4% +$87.7K 0.49% 50
2020
Q2 		$2.31M Buy
23,546
+853
+4% +$75.1K 0.58% 46
2020
Q1 		$1.73M Buy
22,693
+1
+0% +$85 0.46% 48
2019
Q4 		$2.01M Buy
+22,692
New +$1.88M 0.45% 49

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Stokes Family Office's ABBV Position: Q2 2026 in Review

Stokes Family Office reduced its AbbVie (ABBV) stake by 29% in Q2 2026, selling an estimated $1.61M and leaving 18,285 shares worth $4.6M. The position accounts for 0.54% of the portfolio, ranked #57.

Stokes Family Office first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. The position peaked at $6.33M in Q4 2025. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Stokes Family Office held 18,285 shares of AbbVie worth $4.6M as of Q2 2026.
  • Stokes Family Office sold 7,491 AbbVie shares in Q2 2026, an estimated $1.61M.
  • AbbVie made up 0.54% of Stokes Family Office's portfolio in Q2 2026, its #57 holding.
  • Stokes Family Office first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • Stokes Family Office's AbbVie position peaked at $6.33M in Q4 2025.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Stokes Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.